Literature DB >> 23023051

Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union.

Seppo Ylä-Herttuala.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23023051      PMCID： PMC3464639          DOI： 10.1038/mt.2012.194

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  1 in total

1.  The need for increased clarity and transparency in the regulatory pathway for gene medicines in the European Union.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2012-03       Impact factor: 11.454
  1 in total
  129 in total

Review 1.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

Review 2.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

3.  Advancing polymeric delivery systems amidst a nucleic acid therapy renaissance.

Authors:  Paul A Burke; Suzie H Pun; Theresa M Reineke
Journal:  ACS Macro Lett       Date:  2013-10-15       Impact factor: 6.903

4.  Rethinking risk assessment for emerging technology first-in-human trials.

Authors:  Anna Genske; Sabrina Engel-Glatter
Journal:  Med Health Care Philos       Date:  2016-03

5.  Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.

Authors:  Christian Huisman; Monique G P van der Wijst; Fahimeh Falahi; Juul Overkamp; Gellért Karsten; Martijn M Terpstra; Klaas Kok; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman; Marianne G Rots
Journal:  Epigenetics       Date:  2015-04-01       Impact factor: 4.528

Review 6.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 7.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 8.  Human Cardiac Gene Therapy.

Authors:  Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2018-08-17       Impact factor: 17.367

9.  Non-viral gene-activated matrices: next generation constructs for bone repair.

Authors:  Erica G Tierney; Garry P Duffy; Sally-Ann Cryan; Caroline M Curtin; Fergal J O'Brien
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.